Compound 1132
Identifiers
- Canonical SMILES:
OC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)c1c(F)cccc1Cl
- IUPAC name:
(2S)-2-[(2-chloro-6-fluorobenzoyl)amino]-3-(1H-indol-3-yl)propanoic acid
- InChi:
InChI=1S/C18H14ClFN2O3/c19-12-5-3-6-13(20)16(12)17(23)22-15(18(24)25)8-10-9-21-14-7-2-1-4-11(10)14/h1-7,9,15,21H,8H2,(H,22,23)(H,24,25)/t15-/m0/s1
- InChiKey:
KHHMGBVQNFVSEB-HNNXBMFYSA-N
External links
![]() 10383943 |
![]() CHEMBL302644 |
![]() 8559385 |
External search
|
|
|
|
|
Bibliography (1)
Pharmacological data
| Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
|---|---|---|---|
| 1 | 0 | 0 | 0 |
Targets
| PPI family | Best activity | Diseases | MMoA |
|---|---|---|---|
| LFA / ICAM | 6.60 | immune system disease | Inhibition |
Physicochemical filters
| Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
|---|---|---|---|---|
| Compliance | ||||
| MW | 360.07 g/mol | |||
| HBA | 5 | |||
| HBD | 3 | |||
| HBA + HBD | 8 | |||
| AlogP | 3.60 | |||
| TPSA | 82.19 | |||
| RB | 5 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
| Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
|---|---|---|---|---|
| 1 | 1 | 0 | 0 | 0 |
| Ta | Structure | Name | Drugbank ID |
|---|---|---|---|
| 0.6621 | Rebamipide | DB11656 | |
| 0.6552 | Golotimod | DB05475 | |
| 0.6333 | Oglufanide | DB05779 | |
| 0.6316 | N-[1H-INDOL-3-YL-ACETYL]VALINE ACID | DB07953 | |
| 0.6288 | 5-fluorotryptophan | DB03314 | |
| 0.6170 | N-(indole-3-acetyl)-L-aspartic acid | DB07951 | |
| 0.6058 | 4-Fluorotryptophane | DB03386 | |
| 0.6056 | (2s)-2-[(2,4-Dichloro-Benzoyl)-(3-Trifluoromethyl-Benzyl)-Amino]-3-Phenyl-Propionic Acid | DB03605 | |
| 0.5985 | N-[1H-INDOL-3-YL-ACETYL]GLYCINE ACID | DB07952 | |
| 0.5984 | D-Tryptophan | DB03225 | |
| 0.5984 | Tryptophan | DB00150 | |
| 0.5921 | Gramicidin D | DB00027 | |
| 0.5865 | Beta-Hydroxytryptophane | DB04159 | |
| 0.5828 | MK-3577 | DB14957 | |
| 0.5821 | Oxitriptan | DB02959 |




